Evidence map›Paper›PMID 27916154›Full record

ArticleMayo Clinic proceedings2016

Cancer History Portends Worse Acute and Long-term Noncardiac (but Not Cardiac) Mortality After Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction.

Feilong Wang, Rajiv Gulati, Ryan J Lennon, Bradley R Lewis, Jae Park, Gurpreet S Sandhu, R Scott Wright, Amir Lerman, Joerg Herrmann

Abstract read
PubMed Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Short- and long-term outcomes of patients with active cancer presenting with an acute coronary syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  9. Article
  10. What to Do When There Is Something Unexpected?Life (Basel, Switzerland) · 2024
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Index Admission and Thirty-Day Readmission Outcomes of Patients With Cancer Presenting With STEMI.Cardiovascular revascularization medicine : including molecular interventions · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Cancer-Associated Atherothrombosis: The Challenge.The International journal of angiology : official publication of the International College of Angiology, Inc · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Feilong WangDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Rajiv GulatiDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Ryan J LennonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Bradley R LewisDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Jae ParkDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Gurpreet S SandhuDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
R Scott WrightDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Amir LermanDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Joerg HerrmannDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: herrmann.joerg@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo define the effect of a history of cancer on in-hospital and long-term mortality after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). PATIENTS AND

methodsIn this retrospective cohort study of 2346 patients with STEMI enrolled in the Mayo Clinic PCI registry from November 1, 2000, through October 31, 2010, we identified 261 patients (11.1%) with a history of cancer. The in-hospital and long-term outcomes (median follow-up, 6.2 years; interquartile range=4.3-8.5 years), including cardiac and noncardiac death and heart failure hospitalization, of these patients were compared with those of 1313 cancer-negative patients matched on age, sex, family history of coronary artery disease, and date of STEMI.

resultsPatients with cancer had higher in-hospital noncardiac (1.9% vs 0.4%; P=.03) but similar cardiac (5.8% vs 4.6%; P=.37) mortality as matched controls. The group at highest acute mortality risk were those diagnosed as having cancer within 6 months before STEMI (hazard ratio [HR]=7.0; 95% CI, 1.4-34.4; P=.02). At 5 years, patients with cancer had similar cardiac mortality (4.2% vs 5.8%; HR=1.27; 95% CI, 0.77-2.10; P=.35) despite more heart failure hospitalizations (15% vs 10%; HR=1.72; 95% CI, 1.18-2.50; P=.01) but faced higher noncardiac mortality (30.0% vs 11.0%; HR=3.01; 95% CI, 2.33-3.88; P<.001) than controls, attributable solely to cancer-related deaths.

conclusionOne in 10 patients in this contemporary registry of patients undergoing primary PCI for STEMI has a history of cancer. These patients have more than a 3 times higher acute in-hospital and long-term noncardiac mortality risk but no increased acute or long-term cardiac mortality risk with guideline-recommended cardiac care.

Indexed as

Severity of Illness IndexAdultAgedCause of DeathCohort StudiesComorbidityFemaleHospital MortalityHumansMaleMiddle AgedMyocardial InfarctionNeoplasmsPercutaneous Coronary InterventionRetrospective StudiesSurvival Rate

Identifiers

PMID27916154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.